Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smarter pacemaker lead placement spare the heart after surgery?

NCT ID NCT07795541

Disease control Sponsor: Sahlgrenska University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

This trial compares two ways of placing a pacemaker lead in people who develop a slow heart rhythm after cardiac surgery. One method uses conventional right ventricular pacing, while the other uses left bundle branch area pacing, which aims to activate the heart more naturally. The study includes 110 participants with normal heart pumping function and measures changes in heart function over time. The goal is to see whether the newer pacing approach reduces the risk of heart damage that can occur with standard pacing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Left bundle branch area pacing (a device-based pacing strategy) versus conventional right ventricular pacing
What this could lead to
If it works, this could reduce the risk of pacing-induced heart damage and improve long-term heart function in people who need a pacemaker after cardiac surgery.
What could go wrong
The trial is relatively small and early, and the benefit over conventional pacing may be modest or absent in people with normal heart function. There are also procedural risks associated with the newer pacing technique.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * High degree atrioventricular block * Cardiac surgery within 30 days of pacemaker implantation * Written informed consent * Current left ventricular ejection fraction at or above 50% Exclusion Criteria: * Any concomitant condition that results in a life expectancy of less than 1 year * Planned for heart transplant or left ventricular assist device * Current dialysis * Not suitable according to the opinion of the investigators due to characteristics that interfere with the adherence to the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrioventricular block are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrioventricular block

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrioventricular block Cardiac surgery

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.